Safety and efficacy of GEMOX plus donafenib and tislelizumab as first‐line therapy for advanced epithelial malignant biliary tract cancer

AIM: This study was aimed to evaluate the safety and the efficacy of gemcitabine and oxaliplatin (GEMOX) combined with donafenib plus tislelizumab as the first‐line treatment for patients with unresectable biliary tract cancer (BTC). METHODS: This is a prospective single‐center exploratory study. El...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Longrong, Zhang, Ning, Wang, Yixiu, Zhang, Ti, Zhu, Weiping, Mao, Anrong, Zhao, Yiming, Wang, Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278481/
https://www.ncbi.nlm.nih.gov/pubmed/37039263
http://dx.doi.org/10.1002/cam4.5924

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278481/
https://www.ncbi.nlm.nih.gov/pubmed/37039263
http://dx.doi.org/10.1002/cam4.5924

Ejemplares similares